Management of Venous Malformation using Injection of Bleomycin Intralesional: Cases ReportJournal: International Journal of Science and Research (IJSR) (Vol.9, No. 6)
Publication Date: 2020-06-05
Authors : Ariyanto Suryo Karyono; Endang Sjamsudin;
Page : 148-151
Keywords : Venous malformations; Bleomycin; Intralesion injection;
Introduction: Vascular anomalies are among the most common form of congenital and neonatal dysmorphogenesis, which can occur in various areas throughout the body with 60 % located in the head and neck. Percutaneous sclerotherapy developed as a minimally invasive treatment modality for this lesion. Bleomycin is known to have a sclerosing effect on endothelial cells, so it can be used to treat vascular malformations. Objective: This case report aims to analyze the management of venous malformation therapy in the oromaxillofacial region using intralesional Bleomycin injection. Case Report: A 39-year-old female patient diagnosed with simple venous malformations which carried out bleomycin injection at RSUP Dr. Hasan Sadikin Bandung. After there sessions of injection, the lesion was significantly reduced from volume and size by more than 51 % but still could look at different colours (score 3). The patient was satisfied with the results of the treatment, and the lesion was known to show no symptoms of recurrence after control three months postoperatively in the third session. Discussion: The results from the treatment in this case report are similar to the treatment results from several case reports that use Bleomycin as a sclerotherapy agent to treat vascular malformations. The high success and minimal risk of treatment with Bleomycin make it the first choice sclerotherapy agent. Conclusion: Treatment of this case shows that Bleomycin Intralion Injection of venous malformations is an effective non-invasive treatment and has no side effects. Bleomycin sclerosant can be an effective and safe way for nonsurgical treatment options for head and neck vein malformations. Bleomycin is also considered safe with minimal risk in the treatment of venous malformations.
Other Latest Articles
Last modified: 2021-06-28 17:08:00